Inactive Instrument
TetraLogic Pharmaceuticals Corporation Stock Other OTC
Stocks
TLOG
US88165U1097
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 1.52M 1.33M 1.23M 1.15M 2.16M 143M 2.2M 14.76M 5.7M 70.76M 5.7M 5.57M 246M | P/E 2014 |
-2.96x | P/E 2015 | -0.82x |
|---|---|---|---|---|---|
| Enterprise Value | 9.44M 8.27M 7.63M 7.13M 13.42M 893M 13.72M 91.84M 35.46M 440M 35.46M 34.68M 1.53B | EV / Sales 2014 |
-
| EV / Sales 2015 | - |
| Free-Float |
100% | Yield 2014 * |
-
| Yield 2015 | - |
| 1 day | -17.65% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Barie
PSD | President | - | - |
| Director of Finance/CFO | 68 | 30/04/2016 | |
Richard Sherman
LAW | General Counsel | 78 | 01/11/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.65% | -17.65% | - | - | 972 | |
| +3.31% | -0.20% | +72.71% | +128.31% | 55.78B | |
| -1.32% | +16.55% | +89.14% | +101.41% | 55.66B | |
| -0.73% | +3.43% | -11.97% | -13.16% | 23.84B | |
| +2.52% | +5.32% | +6.90% | +409.90% | 22.7B | |
| +4.45% | +5.06% | +36.50% | -30.43% | 16.12B | |
| +0.36% | +6.19% | +23.70% | +185.30% | 13.64B | |
| +5.51% | +22.37% | +171.85% | +333.54% | 14.8B | |
| +1.22% | +4.07% | +76.56% | +131.32% | 12.16B | |
| -1.63% | +7.25% | +159.72% | +163.06% | 11.85B | |
| Average | -0.40% | +6.15% | +69.46% | +156.58% | 25.17B | |
| Weighted average by Cap. | +1.34% | +5.02% | +66.95% | +142.55% |
| 2014 | 2015 | |
|---|---|---|
| Net sales | - | - |
| Net income | -35.96M -31.49M -29.07M -27.14M -51.1M -3.4B -52.26M -350M -135M -1.68B -135M -132M -5.82B | -49.72M -43.54M -40.19M -37.53M -70.65M -4.7B -72.26M -484M -187M -2.32B -187M -183M -8.05B |
| Net Debt | -22.32M -19.54M -18.04M -16.85M -31.71M -2.11B -32.43M -217M -83.81M -1.04B -83.81M -81.97M -3.61B | 7.92M 6.94M 6.41M 5.98M 11.26M 749M 11.52M 77.09M 29.76M 370M 29.76M 29.11M 1.28B |
Employees
-
